ClinicalTrials.gg
Active, not recruitingNCT05476926VOYAGERUpdated Oct 2, 2026

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

An observational study in Neovascular Age-related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion, sponsored by Hoffmann-La Roche. Active, not recruiting at 299 sites in 29 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Hoffmann-La Roche · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
6,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 19 studies in Retinal Vein Occlusion with a site in Japan — none open to participants now, 1 under way, none of them phase 3. Retinal Vein Occlusion · Japan.

Started
2022
the only one that year
Observational
4 of 19
none open now
Registered
18th of 19
by date
Lead sponsor
3 of 19
Hoffmann-La Roche

Among the 19 studies in Retinal Vein Occlusion with a site in Japan, this one is the only one that started in 2022, is one of 4 observational ones, and was the 18th registered.

Retinal Vein Occlusion

290 studies on the registry are indexed under Retinal Vein Occlusion; 32 are open to participants now.

Browse Retinal Vein Occlusion studies →

Open to participants now

None of the 19 studies in Retinal Vein Occlusion with a site in Japan is open now. The open studies under Retinal Vein Occlusion, anywhere →

Who these studies take

Of the 18 Retinal Vein Occlusion studies recruiting now, 13 (72%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Retinal Vein Occlusion with a site in Japan as a file.
02

Study summary

The VOYAGER study is a primary data collection, non-interventional, prospective, multinational, multicenter study. It is designed to collect real-world, long-term data to explore long-term effectiveness, safety, clinical insights, treatment patterns, and factors driving the treatment decisions among patients being treated with specified Roche ophthalmology products in approved retinal indications (Faricimab for neovascular age-related macular degeneration [nAMD], diabetic macular edema [DME], and retinal vein occlusion; Port Delivery System with Ranibizumab for nAMD) in routine clinical practice. This study will not provide or make recommendations on use of any products including Roche products; treatment decisions will be determined by the treating physician and must be made independently to the decision to participate in this study. Participation in this study will not change or influence a patient's standard of care in any way.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration
  • Diabetic Macular Edema
  • Retinal Vein Occlusion
  • Branch Retinal Vein Occlusion
  • Central Retinal Vein Occlusion
  • Hemi-retinal Vein Occlusion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients being treated with specified Roche ophthalmology products approved in retinal indications in real-world, routine clinical practice.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. Have provided , as required per local regulations 2.a) Adult patient, as defined by local regulations and local product label, who is newly initiating treatment (or initiated treatment in the previous visit) with a specified approved Roche ophthalmology product in retinal indication of interest for this study in at least one eye, according to the investigator's discretion in routine clinical practice; OR 2.b) Adult patient, as defined by local regulations and local product label, who is continuing treatment with any specified approved Roche ophthalmology product in retinal indication of interest for this study in at least one eye after initiating that treatment in a Roche interventional trial.

Exclusion criteria

Exclusion Criteria:

1. Concomitant participation of the patient in an ophthalmology clinical trial that includes receipt of any investigational drug or procedure within the last 28 days prior to enrollment (this restriction does not apply to patients who are rolling over from Roche interventional studies and continuing treatment with any specified approved Roche ophthalmology product in retinal indication of interest for this study)

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
6,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort 1: Faricimab for nAMD

    Drug: Faricimab

  • Cohort 2: Faricimab for DME

    Drug: Faricimab

  • Cohort 3: Port Delivery System with Ranibizumab for nAMD

    Combination Product: Port Delivery System with Ranibizumab

  • Cohort 4: Faricimab for BRVO

    Drug: Faricimab

  • Cohort 5: Faricimab for CRVO/HRVO

    Drug: Faricimab

Interventions

  • Faricimab will be administered as per local clinical practice and local labeling.

    Also known as: VABYSMO™, RO6867461, RG7716

  • Combination productPort Delivery System with Ranibizumab

    Drug page: Ranibizumab

    The port delivery system with ranibizumab will be administered as per local clinical practice and local labeling.

    Also known as: SUSVIMO™, RG6321

06

What researchers measure

Primary outcomes

  1. Change in Visual Acuity from Baseline at 1 Year, per Approved Retinal Indication and Product

    Visual acuity will be collected as measured per local practice and then will be converted to the approximate ETDRS letter score.

    Time frame: Baseline and 1 year

Secondary outcomes

  1. Change in Visual Acuity from Baseline Over Time, per Approved Retinal Indication and Product

    Visual acuity will be collected as measured per local practice and then will be converted to the approximate ETDRS letter score.

    Time frame: Baseline, 3, 6, and 12 months, and annually thereafter (up to 5 years)

  2. Percentage of Eyes on Each Treatment Regimen (Fixed, Treat-and-Extend, As Needed, or Other) Over Time, per Approved Retinal Indication and Product

    Time frame: Baseline, 3, 6, and 12 months, and annually thereafter (up to 5 years)

  3. Number of Treatments Over Time, per Approved Retinal Indication and Product

    Time frame: At 3, 6, and 12 months, and annually thereafter (up to 5 years)

  4. Cumulative Time Spent on Each Treatment per Eye, Overall and per Treatment Regimen (Fixed, Treat-and-Extend, As Needed, or Other), per Approved Retinal Indication and Product

    Time frame: From Baseline until end of study (up to 5 years)

  5. Percentage of Eyes with Treatment Switch by Reason for Switch Over Time, per Approved Retinal Indication and Product

    Time frame: At 3, 6, and 12 months, and annually thereafter (up to 5 years)

  6. Percentage of Eyes with Treatment Regimen Switch (Fixed, Treat-and-Extend, As Needed, or Other) by Reason for Switch Over Time, per Approved Retinal Indication and Product

    Time frame: At 3, 6, and 12 months, and annually thereafter (up to 5 years)

  7. Total Number of Visits per Year, per Approved Retinal Indication and Product

    Time frame: Annually (up to 5 years)

  8. Number of Visits With or Without Treatment per Year, per Approved Retinal Indication and Product

    Time frame: Annually (up to 5 years)

  9. Time Interval Between Treatments per Year, per Approved Retinal Indication and Product

    Time frame: Annually (up to 5 years)

  10. Number of Eyes Treated with Ocular Concomitant and Subsequent Medications by Type and Frequency During the Study, per Approved Retinal Indication and Product

    Time frame: From Baseline until end of study (up to 5 years)

  11. Change in Visual Acuity from Baseline Over Time, According to Treatment Regimen (Fixed, Treat-and-Extend, As Needed, or Other), per Approved Retinal Indication and Product

    Visual acuity will be collected as measured per local practice and then will be converted to the approximate ETDRS letter score.

    Time frame: Baseline, 3, 6, and 12 months, and annually thereafter (up to 5 years)

  12. Change in Visual Acuity from Baseline Over Time, According to Number of Treatments, per Approved Retinal Indication and Product

    Visual acuity will be collected as measured per local practice and then will be converted to the approximate ETDRS letter score.

    Time frame: Baseline, 3, 6, and 12 months, and annually thereafter (up to 5 years)

  13. Change in Visual Acuity from Baseline Over Time, According to Total Number of Visits, per Approved Retinal Indication and Product

    Visual acuity will be collected as measured per local practice and then will be converted to the approximate ETDRS letter score.

    Time frame: Baseline, 3, 6, and 12 months, and annually thereafter (up to 5 years)

  14. Change in Visual Acuity from Baseline Over Time, According to Treatment Schedule, per Approved Retinal Indication and Product

    Visual acuity will be collected as measured per local practice and then will be converted to the approximate ETDRS letter score.

    Time frame: Baseline, 3, 6, and 12 months, and annually thereafter (up to 5 years)

  15. Change in Central Subfield Thickness (CST) from Baseline Over Time, per Approved Retinal Indication and Product

    Time frame: Baseline, 3, 6, and 12 months, and annually thereafter (up to 5 years)

  16. Number of Participants with at Least One Ocular Adverse Event, by Severity and Seriousness, per Approved Retinal Indication and Product

    Severity and seriousness will be independently assessed for each adverse event (AE). The terms "severe" and "serious" are not synonymous. Severity refers to the intensity of an AE (e.g., rated as mild, moderate, or severe); the event itself may be of relatively minor medical significance.

    Time frame: From Baseline until end of study (up to 5 years)

  17. Number of Participants with at Least One Non-Ocular Adverse Event, by Severity and Seriousness, per Approved Retinal Indication and Product

    Severity and seriousness will be independently assessed for each adverse event (AE). The terms "severe" and "serious" are not synonymous. Severity refers to the intensity of an AE (e.g., rated as mild, moderate, or severe); the event itself may be of relatively minor medical significance.

    Time frame: From Baseline until end of study (up to 5 years)

07

Study locations

299 sites

Showing the first 100 of 299 sites across 29 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Bailey C, Pearce I, Dinah C, Dodds M, Vidal-Brime L, Wilson A, Ellis J, Hall J, Pohler R, Shi B, Toshev D, Guymer R. Automated data collection from an electronic medical record for a prospective real-world study in patients with retinal disease (VOYAGER). Clin Trials. 2025 Dec;22(6):637-648. doi: 10.1177/17407745251358235. Epub 2025 Aug 31. PubMed 40886069 ↗

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Nov 2026, 48 months after the start.

Of 25 observational studies under Retinal Vein Occlusion, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 69. This study's planned 48 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2022
First posted
Jul 27, 2022
StartActual
Nov 21, 2022
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2027
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
1 update, last Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05476926
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 27, 2022
Start date
Nov 21, 2022
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Oct 2, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion